Dyne Therapeutics (NASDAQ:DYN) Trading Up 3.9%

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) rose 3.9% during trading on Thursday . The company traded as high as $35.30 and last traded at $35.25. Approximately 132,541 shares changed hands during mid-day trading, a decline of 92% from the average daily volume of 1,718,124 shares. The stock had previously closed at $33.92.

Analysts Set New Price Targets

DYN has been the subject of a number of research analyst reports. Jefferies Financial Group raised their price target on Dyne Therapeutics from $36.00 to $42.00 and gave the stock a “buy” rating in a research note on Monday, May 20th. Oppenheimer reaffirmed an “outperform” rating and issued a $47.00 price target on shares of Dyne Therapeutics in a research note on Monday, May 6th. HC Wainwright raised their price target on Dyne Therapeutics from $36.00 to $48.00 and gave the stock a “buy” rating in a research note on Monday, May 20th. Chardan Capital raised their price target on Dyne Therapeutics from $31.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday, May 21st. Finally, Piper Sandler raised their price target on Dyne Therapeutics from $27.00 to $29.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 6th. One equities research analyst has rated the stock with a sell rating, eight have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Dyne Therapeutics has an average rating of “Moderate Buy” and an average price target of $40.78.

Dyne Therapeutics Trading Up 2.3 %

The firm has a 50-day simple moving average of $29.56 and a 200 day simple moving average of $24.26.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Thursday, May 2nd. The company reported ($0.81) earnings per share for the quarter, meeting the consensus estimate of ($0.81). As a group, equities research analysts forecast that Dyne Therapeutics, Inc. will post -3 EPS for the current fiscal year.

Insider Activity

In related news, COO Susanna Gatti High sold 2,738 shares of Dyne Therapeutics stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $28.27, for a total value of $77,403.26. Following the completion of the sale, the chief operating officer now directly owns 154,062 shares in the company, valued at approximately $4,355,332.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, SVP Richard William Scalzo sold 1,590 shares of Dyne Therapeutics stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $30.23, for a total value of $48,065.70. Following the completion of the sale, the senior vice president now directly owns 115,105 shares in the company, valued at approximately $3,479,624.15. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO Susanna Gatti High sold 2,738 shares of Dyne Therapeutics stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $28.27, for a total value of $77,403.26. Following the completion of the sale, the chief operating officer now owns 154,062 shares of the company’s stock, valued at $4,355,332.74. The disclosure for this sale can be found here. Insiders sold 202,133 shares of company stock worth $6,500,387 over the last three months. 20.77% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Dyne Therapeutics

Large investors have recently bought and sold shares of the business. Wetzel Investment Advisors Inc. bought a new stake in shares of Dyne Therapeutics during the 1st quarter valued at about $28,000. Ameritas Investment Partners Inc. grew its stake in shares of Dyne Therapeutics by 28.0% during the 1st quarter. Ameritas Investment Partners Inc. now owns 5,896 shares of the company’s stock valued at $167,000 after purchasing an additional 1,291 shares during the period. China Universal Asset Management Co. Ltd. grew its stake in shares of Dyne Therapeutics by 355.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 7,099 shares of the company’s stock valued at $94,000 after purchasing an additional 5,541 shares during the period. EntryPoint Capital LLC bought a new stake in shares of Dyne Therapeutics during the 1st quarter valued at about $214,000. Finally, SG Americas Securities LLC bought a new stake in shares of Dyne Therapeutics during the 4th quarter valued at about $172,000. 96.68% of the stock is currently owned by institutional investors.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.